Severe hepatocellular dysfunction following cyproterone acetate therapy.
Cyproterone acetate (CPA) is a widely used drug in the treatment of advanced prostatic carcinoma. Although it is generally well tolerated, liver toxicity has been recognised as a complication of long-term use. We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.
Parys
B T
BT
Department of Urology, Royal Preston Hospital, Preston.
Hamid
S
S
Thomson
R G
RG
D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D003534:Cyproterone / Q000009:adverse effects / Q000031:analogs & derivatives*; D017373:Cyproterone Acetate; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents; D017373:Cyproterone Acetate; D003534:Cyproterone